** Shares of Nuvectis Pharma NVCT.O down 18.2% at $23.35 post-market as it looks to raise equity

** Clinical stage biopharma kicks off stock offering; deal size not disclosed

** Cantor Fitzgerald sole bookrunner

** Co intends to use net offering proceeds to advance programs of NXP100, NXP200, and NXP900 or any future product candidate, among other purposes

** NVCT a week ago secured licensing deal with China's Haisco 002653.SZ for experimental drugs NXP100 and NXP200, targeting complement-mediated diseases and cancer to broaden its pipeline

** NVCT shares on Mon rose 4.9% to $28.53, a record high close. Stock has nearly tripled this month, putting it up 278% YTD

** Co has ~26.5 mln shares outstanding for roughly $760 mln market cap

** All 5 analysts rate the stock "buy" and their median PT is $30, per LSEG data